BRIEF published on 11/04/2024 at 11:51, 1 year 1 month ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 1 year 1 month ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 1 month ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 1 month ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 2 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 1 year 2 months ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 2 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 2 months ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 1 year 5 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 5 months ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 12/18/2025 at 00:55, 2 hours 56 minutes ago Molten Metals Corp. Announces Flow-Through Financing
Published on 12/18/2025 at 00:00, 3 hours 51 minutes ago Right Season Investments Announces Name Change to FutureGen Industries Corp.
Published on 12/17/2025 at 23:15, 4 hours 36 minutes ago Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 12 hours 51 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 13 hours 51 minutes ago UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/18/2025 at 01:10, 2 hours 41 minutes ago Samsung To Unveil New AI-Connected Living Lineup at CES 2026
Published on 12/18/2025 at 00:50, 3 hours 1 minute ago Historic production of graphene enhanced cement successfully completed
Published on 12/17/2025 at 22:05, 5 hours 46 minutes ago Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques
Published on 12/17/2025 at 22:05, 5 hours 46 minutes ago Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Published on 12/17/2025 at 21:22, 6 hours 29 minutes ago EQS-Adhoc: DATAGROUP SE: DATAGROUP SE Management Board plans dividend of EUR 0.04 per share
Published on 12/17/2025 at 20:39, 7 hours 12 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 7 hours 12 minutes ago Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 8 hours 21 minutes ago Evolution de la composition du Conseil d’Administration
Published on 12/17/2025 at 18:00, 9 hours 51 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
